9th Edition
The existing medications for treating substance use disorder are underutilized and stigmatized, said Fares Qeadan, associate professor of biostatistics at Loyola University in Chicago
Fido A, Al-Saad S
Paik S, Somvanshi RK, Kumar U (2019) Somatostatin-Mediated Changes in Microtubule-Associated Proteins and Retinoic Acid-Induced Neurite Outgrowth in SH-SY5Y Cells
Ro Offers Eli Lilly's Foundayo, the Newest GLP-1 Innovation Foundayo gives patients a new once daily pill option and expands Ros comprehensive weight loss formulary April 9, 2026 Ro, the leading direct-to-patient healthcare company, today announced eligible patients can now access Foundayo (orforglipron) Eli Lilly Companys newest oral GLP-1 innovation on the Ro platform, adding to Ros already comprehensive formulary of FDA-approved GLP-1s
[Crossref] Ralph D, Gonzalez-Cadavid N, Mirone V, et al